Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03299166 · ClinicalTrials.gov registry record · Phase 2
Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder
A Phase 2 study, sponsored by Biohaven Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 426
- Enrollment target
NCT03299166 is a Phase 2 study that has completed, run by Biohaven Pharmaceuticals. The registered enrollment target is 426 participants.
The verdict
NCT03299166, a Phase 2 study, has completed, sponsored by Biohaven Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 426 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of troriluzole as adjunctive therapy versus placebo in participants with obsessive compulsive disorder (OCD) who had an inadequate response to selective serotonin reuptake inhibitor (SSRI), clomipramine, venlafaxine, or desvenlafaxine treatment
Interventions
- DRUG Placebo
- DRUG Troriluzole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 426 participants |
| Start Date | 2017-12-19 |
| Est. Completion | 2025-12-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03299166
The ClinicalTrials.gov registry entry for NCT03299166 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 426 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biohaven Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03299166 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03299166 about?
NCT03299166 is a clinical study titled "Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder". The purpose of this study is to evaluate the efficacy of troriluzole as adjunctive therapy versus placebo in participants with obsessive compulsive disorder (OCD) who had an inadequate response to selective serotonin reuptake inhibitor (SSRI), clomipramine, venlafaxine, or desvenlafaxine treatment
What is the current status of trial NCT03299166?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 426 participants. The study started on 2017-12-19. Estimated completion is 2025-12-08.
What interventions are being tested in trial NCT03299166?
The interventions under investigation include: Placebo (DRUG), Troriluzole (DRUG).
Who is sponsoring clinical trial NCT03299166?
This trial is sponsored by Biohaven Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.